Bloom
Diagnostics’ new inflammation test that measures CRP is its latest innovation
in cloud-based healthcare solutions for professional use
Swiss
medtech company Bloom Diagnostics has today
announced the launch of the Bloom Inflammation Test, designed to test for the
quantitative measurement and presence of the C-Reactive Protein (CRP) using the
Bloom system. The Bloom Inflammation Test is designed to be used by
professional clinicians, allowing doctors and pharmacists to rapidly measure
and quantify inflammation in anyone 18 years old and above. Based in Zurich,
Switzerland, Bloom Diagnostics is an innovative medtech company that has
developed a smart system to detect for a wide range of medical conditions.
The Bloom Inflammation Test is a single-use
semi-automated testing kit for the quantitative measurement of CRP in the
bloodstream to detect inflammation in the body. Elevated CRP can be caused by a
range of different medical conditions including asthma, arthritis, COPD,
diabetes, Crohn's disease, pneumonia, and more.
The Bloom Inflammation Test provides five
different classifications depending on the CRP levels contained in the sample
tested, ranging from Normal all the way to a High-Grade Inflammation. It
enables healthcare professionals to test for levels of CRP from a single drop
of blood and receive accurate results in minutes. It follows Bloom’s
specialized ovarian reserve, ferritin, and thyroid tests, aimed at providing
users access to a range of at-home and clinical tests, relieving pressure on
GPs and strained healthcare systems.
The single-use kit for professional
quantitative examination of the C-Reactive Protein is designed for adults aged
18 years of age and over, excluding pregnant users. Pin-prick blood samples are
captured in a test strip, which is then deployed into the Bloom Lab.
Cloud-based algorithms and AI technology aggregate test results with other
input information about health status alongside medical history, lifestyle, and
individual symptoms. Fully encrypted feedback is delivered through a
personalized report on the Bloom App after just 20 minutes.
Bloom Diagnostics was founded in 2018 by Dr.
Angelica Kohlmann and Tom Kupper. In 2020 and 2021 the company closed funding
rounds to further strengthen R&D and drive expansion throughout Europe.
Bloom Diagnostics’ early investors include Speedinvest from Austria and the
Canadian Walter Group. Bloom Diagnostics aims to rapidly add meaningful new
features to its range of capabilities to accelerate the pace of clinical
discoveries and, ultimately, the development of new therapies.
Research published by NHLBI in Bethesda
found high concentrations of C-Reactive Protein present in half of the test
subjects who also displayed inflammatory conditions. While research experts
state that each case of CRP levels should be considered individually,
concentration of the protein is a significant marker for wider health
conditions, and so a valuable tool for clinicians.
Commenting on the latest announcement, Dr. Angelica Kohlmann, MD PhD, Co-founder and Chairperson at Bloom
Diagnostics, said: “Bloom’s main goal is to
create awareness that testing, in general, is the best measure for preventing
or treating serious conditions. The ability to test for CRP is an important
element for clinicians and doctors, and we are proud to be helping advance
medical technology by adding this test to the Bloom Lab’s capabilities.
“For Bloom as a young company, spreading to new geographies
is always a challenge. Every country has its specificities. We see great new
opportunities in the UK and Italy, as we consider both countries to be very
open, with many first adopters when it comes to new technologies. I remember
when the first mobiles came to market and I hardly knew anyone in Germany with
such a device. I travelled to Italy and everyone had one!”
Commenting on the latest announcement, Tom Kupper, Co-founder and Chief Product Officer (CPO) at Bloom
Diagnostics, said: “Inflammation is a common symptom across many ailments, and we
estimate that over half the adult population could benefit from more frequent
testing. Inflammation correlates with diet, exercise and medical conditions,
such as diabetes and arthritis. Introducing a simple and accessible tool to
measure and quantify the body's inflammatory status can be incredibly
impactful. We're very excited to finally launch the Bloom Inflammation Test.”
“We are thrilled to
add two major European countries and close to 130 million people to our
business activities with the UK and Italy - more than doubling Bloom's current
reach. In the medical space, no two countries can be treated alike, as
healthcare systems differ widely. Therefore we always carefully adjust our
strategy for all geographies.”
No comments:
Post a Comment